Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors.
Ontology highlight
ABSTRACT: Immunotherapy has revolutionized the treatment of both hematological malignancies and solid tumors. The use of immunotherapy has improved outcome for patients with cancer across multiple tumor types, including lung, melanoma, ovarian, genitourinary, and more recently breast cancer with durable responses seen even in patients with widespread metastatic disease. Despite the promising results, immunotherapy still helps only a subset of patients due to overall low response rates. Moreover, the response to immunotherapy is highly cancer specific and results have not been as promising in cancers that are considered less immunogenic. The strategies to improve immunotherapy responses have focused on biomarker selection, like PD-L1 status, and usage of combinatorial agents, such as chemotherapy, ta
SUBMITTER: Vikas P
PROVIDER: S-EPMC7228136 | biostudies-literature | 2020
REPOSITORIES: biostudies-literature
ACCESS DATA